|
|
Article: (18 F) (alpha)-methyl tyrosine PET studies in patients with brain tumors
- Article from:
- The Journal of Nuclear Medicine
- Article date:
- March 1, 1999
- Author:
CopyrightCopyright Society of Nuclear Medicine Mar 1999. Provided by ProQuest LLC. (Hide copyright information)
|
We have developed '8F-labeled oz-methyl tyrosine (FMT) for PET imaging. The aim of this study was to evaluate the clinical application potential of FMT for patients with brain tumors. Methods: Eleven healthy volunteers and 20 patients with brain tumors were injected with 185 MBq (5 mCi) FMT. In 3 healthy volunteers, whole-body imaging and urinary and plasma analysis were conducted for the assessment of the biodistribution of FMT. The normal range of cortical standardized uptake value (SUV) as a reference for comparing tumor SUV of FMT was estimated by using PET data obtained at 30 min postinjection in 8 healthy volunteers. Dynamic PET scans were conducted for 100 min in 4 healthy volunteers ...